Renindra Ananda Aman

Dr. Renindra Ananda Aman

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
DPDon Augusto Alexandro Petonengan
Don Augusto Alexandro Petonengan
MHMuhammad Hafif
Muhammad Hafif
FSFabianto Santoso
Fabianto Santoso
Aman RA, et al. J Clin Neurol. 2023 Jan;19:e4. https://doi.org/10.3988/jcn.2022.0116

14 June 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
STSteven Tandean
Steven Tandean
IJIskandar Japardi
Iskandar Japardi
MRMuhammad Rusda
Muhammad Rusda
RIRr Suzy Indharty
Rr Suzy Indharty
ALAznan Lelo
Aznan Lelo
FZFelix Zulhendri
Felix Zulhendri
Stroke is the world’s second-leading cause of death. Current treatments for cerebral edema following intracerebral hemorrhage (ICH) mainly involve hyperosmolar fluids, but this approach is often inadequate. Propolis, known for its various beneficial properties, especially antioxidant and anti-inflammatory properties, could potentially act as an adjunctive therapy and help alleviate stroke-associated injuries. The chemical composition of Geniotrigona thoracica propolis extract was analyzed by GC-MS after derivatization for its total phenolic and total flavonoid content. The total phenolic content and total flavonoid content of the propolis extract were 1037.31 ± 24.10 μg GAE/mL and 374.02 ± 3.36 μg QE/mL, respectively. By GC-MS analysis, its major constituents were found to be triterpenoids (22.4% of TIC). Minor compounds, such as phenolic lipids (6.7% of TIC, GC-MS) and diterpenic acids (2.3% of TIC, GC-MS), were also found. Ninety-six Sprague Dawley rats were divided into six groups; namely, the control group, the ICH group, and four ICH groups that received the following therapies: mannitol, propolis extract (daily oral propolis administration after the ICH induction), propolis-M (propolis and mannitol), and propolis-B+A (daily oral propolis administration 7 days prior to and 72 h after the ICH induction). Neurocognitive functions of the rats were analyzed using the rotarod challenge and Morris water maze. In addition, the expression of NF-κB, SUR1-TRPM4, MMP-9, and Aquaporin-4 was analyzed using immunohistochemical methods. A TUNEL assay was used to assess the percentage of apoptotic cells. Mannitol significantly improved cognitive–motor functions in the ICH group, evidenced by improved rotarod and Morris water maze completion times, and lowered SUR-1 and Aquaporin-4 levels. It also significantly decreased cerebral edema by day 3. Similarly, propolis treatments (propolis-A and propolis-B+A) showed comparable improvements in these tests and reduced edema. Moreover, combining propolis with mannitol (propolis-M) further enhanced these effects, particularly in reducing edema and the Virchow-Robin space. These findings highlight the potential of propolis from the Indonesian stingless bee, Geniotrigona thoracica, from the Central Tapanuli region as a neuroprotective, adjunctive therapy.

1 January 2024 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
YMYovanka Naryai Manuhutu
Yovanka Naryai Manuhutu
MRMuhamad Aulia Rahman
Muhamad Aulia Rahman
NCNicholas Calvin
Nicholas Calvin
YPYutha Perdana
Yutha Perdana
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.

3 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
RSRisayogi W. A. H. Sitorus
Risayogi W. A. H. Sitorus
MRMuhamad Aulia Rahman
Muhamad Aulia Rahman
FSFabianto Santoso
Fabianto Santoso
RKRamadhan Kurniawan
Ramadhan Kurniawan
Tuberculum sellae meningioma (TSM) is a challenging tumor that grows close to several crucial structures, such as the optic nerve, arteries, and pituitary. Surgical treatment is currently evolving from a transcranial microsurgical resection to a transsphenoidal approach. This study examined the clinical profile of patients with tuberculum sellae meningioma and explored its relationship with scoring systems. This retrospective observational study included patients with TSM who underwent surgery at the Department of Neurosurgery at our hospital between 2017 and 2022. The patients were excluded if their data required completion. The clinical profiles of the patients were counted and transformed into a scoring system using several variables such as size, vascular, and canal invasion. We then analyzed the relationship between the clinical signs and symptoms to determine the efficacy of this scoring system. Thirty-six patients were included in the study. Most of our patients had a high score for tumor diameter, bilateral canal invasion, and vascular invasion (2-2-2). Moreover, when related to clinical signs, there was no relationship between the canal and vascular invasion and decreased visual acuity. Tuberculum sellae meningioma mostly causes visual impairment and several other symptoms, such as hemianopsia and parasellar extension. Several factors in the scoring system should also be considered to predict outcomes, such as the onset of visual symptoms, peritumoral edema, and grade of excision.

6 June 2025 in Folia Medica
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
FDFitrie Desbassarie
Fitrie Desbassarie
ALAltair Rahman Lubis
Altair Rahman Lubis
IAIrfani Ryan Ardiansyah
Irfani Ryan Ardiansyah
Introduction: Glioblastoma is a highly aggressive brain cancer with poor prognosis. Recurrence is common, and survival post-recurrence is limited. Identifying prognostic factors for recurrent glioblastoma can optimize treatment and improve outcomes. Aim: This systematic review analyzed the clinical, molecular, and treatment-related variables that influence survival in patients with recurrent glioblastoma. Materials and methods: A comprehensive search of PubMed, Scopus, and ProQuest databases included studies from the past decade, assessed using the Newcastle-Ottawa Scale (NOS). Results: Sixteen studies were analyzed, highlighting age, Karnofsky Performance Status (KPS), molecular markers (MGMT promoter methylation, IDH mutations, TERT promoter mutations, TP53 alterations, ATRX loss, and Ki-67 expression), and surgical resection extent as key prognostic factors. Younger patients with higher KPS scores and favorable molecular markers had better survival. Molecular profiling and maximal resection correlated with improved overall survival (OS). Salvage therapies like chemotherapy and re-resection provided marginal benefits, with variability based on patient demographics and tumor genetics. Conclusion: Age, KPS, molecular markers, and surgical resection extent significantly predict survival in recurrent glioblastoma. The review underscores the importance of molecular profiling for personalized treatment, though current salvage therapies show limited effectiveness. Innovative approaches are needed to enhance outcomes for this aggressive disease. Abbreviations used in the article: BSC: best supportive care; CRE: complete resection of enhancing tumor; DFS: disease-free survival; GBM: glioblastoma; GTR: gross total resection; KPS: Karnofsky Performance Status; NOS: Newcastle-Ottawa Scale; OS: overall survival; PFS: progression-free survival; rGBM: recurrent glioblastoma multiforme; RTOG–RPA: Radiation Therapy Oncology Group – Recursive Partitioning Analysis; TTF: tumor-treating fields

22 November 2024 in Surgical Neurology International
Verified
Journal Article
Open access
NCNicholas Calvin
Nicholas Calvin
RARenindra Ananda Aman
Renindra Ananda Aman
Background: Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis. The current gold standard for GBM treatment, known as the Stupp protocol, includes maximal safe surgical resection followed by radiotherapy and temozolomide chemotherapy. Despite extending survival modestly, this regimen is associated with significant side effects and limited efficacy, resulting in a median survival (MS) of 15 months and a 5-year survival rate of only 7%. A major challenge in GBM treatment is the blood–brain barrier (BBB), which restricts the penetration of therapeutic agents into the brain, thereby limiting the effectiveness of systemic therapies. To address these limitations, this systematic review and meta-analysis investigated the effectiveness of injectable local drug delivery systems (DDS) compared to systemic DDS in murine GBM models. This study aimed to provide robust evidence supporting the potential benefits of injectable local DDS for GBM treatment. Methods: A comprehensive literature search was conducted using PubMed, Embase, and ScienceDirect databases. The studies included were original research on local DDS of anticancer agents compared to systemic DDS in orthotopic GBM tumor models. The data extraction process included information on survival rates, tumor growth, and other relevant outcomes. Statistical analysis was performed using Review Manager 5.4, employing a random-effects model to calculate the pooled mean difference (MD) in survival time between local and systemic DDS. Results: Out of 1341 records, six studies met the inclusion criteria, totaling 129 murine models. The meta-analysis revealed that local injection of DDS significantly improved the MS compared to systemic administration (MD = 2.76; 95% confidence interval, 0.43–5.09; P = 0.03; I2 = 93%). The local injection of the DDS bypassed the BBB, achieving higher local drug concentrations and sustained release at the tumor site, leading to enhanced therapeutic efficacy and reduced systemic toxicity. Conclusion: This systematic review and meta-analysis provide compelling evidence that local injection of DDS significantly improves survival in GBM models compared with systemic therapies. These findings highlight the potential of local DDS to overcome the challenges posed by the BBB and deliver higher concentrations of therapeutic agents directly to the tumor site. However, further research is needed to validate these findings in human clinical trials and refine DDS formulations. Future research should focus on developing DDS formulations capable of delivering multiple therapeutic agents simultaneously, addressing the experimental variability in preclinical models, and conducting rigorous clinical trials to evaluate the safety and efficacy of local DDS in human patients. Standardizing the testing methods across studies will facilitate more accurate comparisons and data integration, ultimately advancing the clinical translation of this promising therapeutic approach.